A program to help Black adults quit smoking
Official title: Comparing Three Multicomponent Interventions to Help Adults Quit Smoking
Run by University of Wisconsin, Madison · NCT07419425 · Data updated 2026-11-12
This trial tests three different, culturally tailored smoking-cessation approaches to see which helps Black adults quit smoking over 26 weeks.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 1550 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 5 sites (Phoenix, Arizona and 4 other locations) |
| Status | Recruiting |
| Started | July 6, 2026 |
| Main results expected | January 2030 |
| Study ends | January 2030 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07419425 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Self-identified Black adults who smoke at least 1 cigarette on 4 or more days per week, are motivated to quit, and willing to discontinue non-study cessation medications during treatment.
✕Probably not a fit
Individuals who do not respond to the specific cessation strategies studied or who are not motivated to quit may not experience a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 4 study compares Standard, Intensive, and Intensive Incentivized treatments for long-term abstinence from combusted tobacco among Black adults who want to quit. Participants receive a combination of nicotine patch, quitline counseling, in-person counseling (Pathways to Freedom), and monetary incentives, with outcomes assessed at 8 and 26 weeks after the target quit day. The primary goal is to identify which approach most effectively increases biochemically confirmed abstinence and improves patient-centered outcomes such as satisfaction and quality of life. Secondary aims include exploring subgroups that benefit most and measuring engagement with treatment components. The study is led by the University of Wisconsin–Madison, with partnerships from PCORI and several affiliated sites nationwide.
Why it matters
Potential benefit: If successful, the most effective approach could lead to higher long-term quit rates for Black adults and inform future, culturally tailored cessation programs.
How similar studies have gone: Earlier research suggests culturally tailored cessation strategies can improve quit rates, but this exact multi-arm, incentives-based comparison is novel in this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * self-identify as Black * smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days/week) * motivated to quit smoking * willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment. Exclusion Criteria: * currently taking bupropion for non-smoking cessation reasons
Where it's running
-
UW School of Medicine and Public Health
Milwaukee, Wisconsin, United States Recruiting -
Arizona State University
Phoenix, Arizona, United States Not yet recruiting -
Indiana University
Indianapolis, Indiana, United States Not yet recruiting -
University of Kansas Medical Center Research Institute, Inc
Kansas City, Kansas, United States Not yet recruiting -
Virginia Commonwealth University
Richmond, Virginia, United States Not yet recruiting
Study contacts
- Principal investigator: Megan Piper, PhD — UW School of Medicine and Public Health
- Study coordinator: Megan Piper, PhD
- Email: mep@ctri.wisc.edu
- Phone: 608-265-5472
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Quitting Matters: a smoking quit program for people living with HIV
This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.
-
Smoky Futures: Danish Adolescent Nicotine Use over Time
This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.
-
Nicotine Orodispersible Tablet to Relieve Cravings in Smokers
A nicotine mint orodispersible tablet is tested vs placebo to see if it quickly eases the urge to smoke in adult cigarette smokers.
-
Optimizing when weekly chatbot reminders go out to people using a chatbot for quitting smoking
This study tests whether sending weekly reminders at different times helps people stay engaged with a chatbot smoking-cessation service.
-
NMDA and Sigma-1 combination therapy for smoking cessation with AXS-05
This phase 3 trial tests whether AXS-05 can help adults quit smoking better than placebo or bupropion.
-
AI-assisted interactive case-based training to improve smoking cessation counseling by medical interns
This study tests whether AI-powered interactive case-based training helps medical interns provide better smoking cessation counseling.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.